Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors

Area of Science:

• Medicinal Chemistry
• Cancer Immunotherapy
• Enzyme Inhibition

Background:

• Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors are promising cancer immunotherapies.
• Existing IDO1 inhibitors like linrodostat contain quinoline moieties susceptible to oxidative metabolism.

Purpose of the Study:

• To identify novel IDO1 inhibitors with improved metabolic stability.
• To discover alternative aromatic systems to replace quinolines in IDO1 inhibitors.

Main Methods:

• Exploration of 2,3-disubstituted pyridines as replacements for quinoline.
• Optimization of physicochemical properties, including ClogP reduction.
• Strategic incorporation of fluorine atoms.
• Evaluation of compound 29's potency, selectivity, and pharmacodynamic activity in a mouse xenograft model.

Main Results:

• Discovery of 2,3-disubstituted pyridines as viable alternatives to quinolines.
• Identification of compound 29 as a potent and selective IDO1 inhibitor.
• Demonstration of robust pharmacodynamic activity for compound 29 in vivo.

Conclusions:

• Compound 29 represents a promising next-generation IDO1 inhibitor.
• The developed pyridine-based scaffold offers an improved alternative to quinoline-based structures.
• Further development of compound 29 may advance cancer immunotherapy.